The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab in combination with the oncolytic virus pelareorep in patients progressing on systemic chemotherapy for advanced pancreatic adenocarcinoma: A phase II study.
 
Devalingam Mahalingam
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - Bristol-Myers Squibb; BTG; Eisai; Exelixis; Ipsen
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis
 
Sheetal Mehta Kircher
Stock and Other Ownership Interests - Abbott/AbbVie; Penrose
 
Victoria Maurer
No Relationships to Disclose
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Jiahui Xu
No Relationships to Disclose
 
Pedro Antonio Hermida de Viveiros
No Relationships to Disclose
 
Elena Vagia
No Relationships to Disclose
 
Grey A Wilkinson
Employment - Oncolytics
Stock and Other Ownership Interests - Oncolytics
 
Matthew C. Coffey
Employment - Oncolytics
Leadership - Oncolytics
Stock and Other Ownership Interests - Oncolytics
 
Mary Frances Mulcahy
Research Funding - BTG
 
Al Bowen Benson
Consulting or Advisory Role - Astellas Pharma; AXIO Research; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Guardant Health; inVentiv Health; Lilly; LSK BioPharma; Merck; NCCN; Purdue Pharma; Rafael Pharmaceuticals; Terumo; TheraBionic
Research Funding - Acerta Pharma; advanced accelerator applications (Inst); Bristol-Myers Squibb; Celgene; Infinity Pharmaceuticals (Inst); MedImmune; Merck Sharp & Dohme (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Xencor
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Dava Oncology; Genentech/Roche; Gilead Sciences; Guardant Health; guerbet; Helsinn Healthcare; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology
 
Bin Zhang
No Relationships to Disclose